The TACT trial: why IV chelation in Louisville is evidence-based.

What TACT is, and why it matters

TACT stands for the Trial to Assess Chelation Therapy. It was a double-blind, placebo-controlled, randomized trial funded by the National Institutes of Health and published in the Journal of the American Medical Association in March 2013 (Lamas et al., JAMA 2013;309:1241 to 1250). The lead investigator was Dr. Gervasio Lamas, MD, a Harvard-educated cardiologist at Mount Sinai Medical Center in Miami Beach. The trial enrolled 1,708 patients, all of whom had already survived a heart attack, and followed them for an average of 55 months to see whether IV EDTA chelation therapy would reduce subsequent cardiovascular events.

The primary endpoint was a composite of death, reinfarction, stroke, coronary revascularization, and hospitalization for angina. In the full trial population, chelation therapy reduced that composite endpoint by 18 percent versus placebo (hazard ratio 0.82, 95% confidence interval 0.69 to 0.99, p equals 0.035). The effect was larger in patients with diabetes at baseline, who saw a 41 percent reduction in major cardiovascular events. Coronary revascularization procedures fell by 26 percent. The five-year number needed to treat to prevent one event was 18 patients.

Why most cardiologists did not learn about this

Chelation therapy had a reputation problem before TACT. For decades, EDTA chelation was used off-label for cardiovascular disease by integrative physicians without the kind of peer-reviewed, randomized data cardiologists require. TACT was commissioned precisely to resolve the question. When the results arrived, they were positive. But the cultural lag in medicine is long, and most practicing cardiologists still treat chelation as investigational or alternative rather than as a standard option for appropriate patients.

At Kentuckiana Integrative Medicine we take the opposite view. The data is published, the sample size is adequate, the endpoints are hard, and the effect is meaningful. That is the basis on which we offer IV chelation as a supportive, off-label option to appropriately screened patients with advanced heart disease, peripheral artery disease, brain vascular disease, and diabetic vascular complications. Individual patient results vary.

The KIM protocol: chelation paired with Plaquex

Our cardiovascular protocol follows the TACT framework and adds IV Plaquex (phosphatidylcholine), which targets the lipid component of vascular plaque. A full cardiovascular course typically runs 40 to 60 sessions over 12 to 24 months, paired with a heart and blood-vessel wellness screening package at baseline and at follow-up. IV EDTA chelation sessions price at $130 to $175 per session, and Plaquex sessions price at $170 to $175 per session.

Dr. Cruz is certified in chelation therapy through the American College of Complimentary Medicine. Every infusion is administered in the clinic, with physician oversight, in an IV room designed for long-session comfort. Our team runs baseline labs and follow-up vascular imaging so we can measure what we are doing, the same way TACT did.

Who the evidence supports, and who it does not

TACT was run in post-heart-attack patients. The diabetic subgroup showed the strongest benefit (TACT trial, JAMA 2013, NIH-funded). If you fall into that category, the published evidence for chelation supports further conversation. We also observe favorable outcomes in patients with peripheral artery disease, advanced carotid narrowing, and brain vascular disease (internal clinical observations; individual results vary), though those indications extrapolate from TACT rather than sit inside its primary population.

Chelation is not for everyone. Patients with significant kidney dysfunction require careful screening or different therapy. Patients on certain medications need review. These are conversations we have at the consultation, not after booking. Our job is to tell you, plainly, whether the evidence supports your case and what your number would look like if we treated.

Further reading

We host several TACT-related documents on our resources page, including a plain-language explainer and the highlighted Circulation / American Heart Association paper. If you want to see the service details, visit the cardiovascular service page, or request a consultation.